CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
ID: 354796Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354796

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-24-005.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity under the CCRP Initiative to support research on the mechanisms of chemical threat agents that impact pulmonary and ocular health. The objective is to identify biological pathways and potential molecular targets to mitigate acute and chronic health effects from exposure to Chemicals of Concern (CoC), with a focus on diverse models and various biological variables. This initiative is crucial for enhancing medical countermeasure development in response to public health threats associated with toxic chemical releases. Interested applicants can request up to $300,000 per year for a maximum of three years, with applications due by September 24, 2026, and projects expected to start in March 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-24-005.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-ES-24-005-Full-Announcement.html
    RFA-ES-24-005.html
    The National Institutes of Health (NIH) has issued a funding opportunity to support research on the mechanistic understanding of chemical threat agents that affect pulmonary and ocular health through the CCRP Initiative. This research aims to identify the biological pathways and potential molecular targets for mitigating acute and chronic adverse health effects due to exposure to identified Chemicals of Concern (CoC). Applications are invited for projects using diverse models, focusing on both pulmonary and ocular toxicities, within a maximum budget of $300,000 per year over a three-year project period. The deadline for applications is set for September 24, 2026, with an earliest start date for projects in March 2025. The NOFO emphasizes the importance of studying multiple toxicants, various time points, and incorporating a range of biological variables. Notably, the initiative does not approve clinical trials applications and requires adherence to strict application guidelines to ensure safety during research. Overall, this funding aims to enhance medical countermeasure development in response to high-consequence public health threats linked to toxic chemical releases.
    Similar Opportunities
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT), aimed at supporting the early-stage development of therapeutics to mitigate health impacts from toxic chemical exposures. This initiative focuses on identifying and validating therapeutic candidates that can address the effects of chemical warfare agents and toxic industrial chemicals, particularly in large-scale public health emergencies. Eligible applicants, including higher education institutions, nonprofits, and tribal governments, can request funding up to $350,000 annually for the UG3 phase and $450,000 for the UH3 phase, with applications due by October 17, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants," aimed at fostering community-engaged research to identify and mitigate health risks associated with environmental exposures. This initiative encourages multidisciplinary projects that actively involve community members in defining research questions and methodologies, with the goal of developing actionable public health plans based on research findings. The program is particularly focused on addressing health disparities and promoting environmental health justice, with a maximum funding amount of $500,000 available for direct costs over a period of up to five years. Interested applicants can find more information and apply by visiting the provided link or contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by September 7, 2025.
    Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)" aimed at supporting early-stage translational research for developing therapeutic agents targeting heart, lung, blood, and sleep disorders. This initiative seeks to identify lead compound series and bridge the gap between basic science discoveries and preclinical testing, emphasizing innovation through novel therapeutic approaches and strong biological rationale. The grant offers a maximum funding amount of $350,000 over a two-year period, with no cost-sharing requirement, and applications are due by December 20, 2024. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html.
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Time-Sensitive Research Opportunities in Environmental Health Sciences" (NOFO RFA-ES-23-011) aimed at supporting urgent research in environmental health. This initiative focuses on addressing pressing environmental health issues arising from unpredictable events, such as natural disasters and policy changes, facilitating rapid data collection and analysis of human biological samples. With a total budget of $800,000 annually and individual awards capped at $275,000 over a maximum of two years, the program emphasizes an expedited review process, allowing for a complete cycle from submission to award within 4-6 months. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with applications due by December 1, 2025.
    Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 grant titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development," aimed at supporting exploratory research projects focused on radiation exposure and its medical countermeasures. The initiative seeks innovative proposals that address the development of biodosimetry techniques, medical countermeasures for radiation injuries, and animal model development, with an emphasis on high-risk, high-reward research that can enhance public health emergency preparedness. The total funding available is approximately $2 million, with individual awards capped at $100,000 per year for a maximum of two years. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.